Boehringer Ingelheim Pharma GmbH & Co. KG has prepared and tested heteroaromatic compounds described as GTPase KRAS G12C mutant inhibitors and reported to be useful for the treatment of cancer.
Immunic AG has identified deuterated dihydroorotate dehydrogenase (DHODH) inhibitors containing a carboxylic acid bioisostere. They are reported to be useful for the treatment of Crohn’s disease, influenza, lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, SARS-CoV-2 infection (COVID-19) and cancer, among others.
A Gossamer Bio Inc. patent describes oxime derivatives that act as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors and are thus reported to be useful for the treatment of cancer and viral infections.
Several patents from Bristol Myers Squibb Co. describe relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of heart failure and fibrosis.
Shanghai Maxinovel Pharmaceuticals Co. Ltd. has reported the identification of programmed cell death 1 (PD-1; PDCD1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed nitrogenous heterocyclic compounds described as as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.
Innovstone Therapeutics Ltd. has described aromatic heterocyclic compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors potentially useful for the treatment of pancreatic cancer, heart failure and myocardial infarction.
RSS